First Time Loading...
A

Ambrx Biopharma Inc
NYSE:AMAM

Watchlist Manager
Ambrx Biopharma Inc
NYSE:AMAM
Watchlist
Price: 28 USD 0.07% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

AMAM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Ambrx Biopharma Inc. operates as a clinical-stage biologics company. [ Read More ]

The intrinsic value of one AMAM stock under the Base Case scenario is 0.63 USD. Compared to the current market price of 28 USD, Ambrx Biopharma Inc is Overvalued by 98%.

Key Points:
AMAM Intrinsic Value
Base Case
0.63 USD
Overvaluation 98%
Intrinsic Value
Price
A
Base Case Scenario

Valuation Backtest
Ambrx Biopharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AMAM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Ambrx Biopharma Inc

Provide an overview of the primary business activities
of Ambrx Biopharma Inc.

What unique competitive advantages
does Ambrx Biopharma Inc hold over its rivals?

What risks and challenges
does Ambrx Biopharma Inc face in the near future?

Has there been any significant insider trading activity
in Ambrx Biopharma Inc recently?

Summarize the latest earnings call
of Ambrx Biopharma Inc.

What significant events have occurred
in Ambrx Biopharma Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ambrx Biopharma Inc.

Provide P/S
for Ambrx Biopharma Inc.

Provide P/E
for Ambrx Biopharma Inc.

Provide P/OCF
for Ambrx Biopharma Inc.

Provide P/FCFE
for Ambrx Biopharma Inc.

Provide P/B
for Ambrx Biopharma Inc.

Provide EV/S
for Ambrx Biopharma Inc.

Provide EV/GP
for Ambrx Biopharma Inc.

Provide EV/EBITDA
for Ambrx Biopharma Inc.

Provide EV/EBIT
for Ambrx Biopharma Inc.

Provide EV/OCF
for Ambrx Biopharma Inc.

Provide EV/FCFF
for Ambrx Biopharma Inc.

Provide EV/IC
for Ambrx Biopharma Inc.

Show me price targets
for Ambrx Biopharma Inc made by professional analysts.

What are the Revenue projections
for Ambrx Biopharma Inc?

How accurate were the past Revenue estimates
for Ambrx Biopharma Inc?

What are the Net Income projections
for Ambrx Biopharma Inc?

How accurate were the past Net Income estimates
for Ambrx Biopharma Inc?

What are the EPS projections
for Ambrx Biopharma Inc?

How accurate were the past EPS estimates
for Ambrx Biopharma Inc?

What are the EBIT projections
for Ambrx Biopharma Inc?

How accurate were the past EBIT estimates
for Ambrx Biopharma Inc?

Compare the revenue forecasts
for Ambrx Biopharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ambrx Biopharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ambrx Biopharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ambrx Biopharma Inc compared to its peers.

Compare the P/E ratios
of Ambrx Biopharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ambrx Biopharma Inc with its peers.

Analyze the financial leverage
of Ambrx Biopharma Inc compared to its main competitors.

Show all profitability ratios
for Ambrx Biopharma Inc.

Provide ROE
for Ambrx Biopharma Inc.

Provide ROA
for Ambrx Biopharma Inc.

Provide ROIC
for Ambrx Biopharma Inc.

Provide ROCE
for Ambrx Biopharma Inc.

Provide Gross Margin
for Ambrx Biopharma Inc.

Provide Operating Margin
for Ambrx Biopharma Inc.

Provide Net Margin
for Ambrx Biopharma Inc.

Provide FCF Margin
for Ambrx Biopharma Inc.

Show all solvency ratios
for Ambrx Biopharma Inc.

Provide D/E Ratio
for Ambrx Biopharma Inc.

Provide D/A Ratio
for Ambrx Biopharma Inc.

Provide Interest Coverage Ratio
for Ambrx Biopharma Inc.

Provide Altman Z-Score Ratio
for Ambrx Biopharma Inc.

Provide Quick Ratio
for Ambrx Biopharma Inc.

Provide Current Ratio
for Ambrx Biopharma Inc.

Provide Cash Ratio
for Ambrx Biopharma Inc.

What is the historical Revenue growth
over the last 5 years for Ambrx Biopharma Inc?

What is the historical Net Income growth
over the last 5 years for Ambrx Biopharma Inc?

What is the current Free Cash Flow
of Ambrx Biopharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ambrx Biopharma Inc.

Financials

Balance Sheet Decomposition
Ambrx Biopharma Inc

Current Assets 233.8m
Cash & Short-Term Investments 225.3m
Receivables 2.4m
Other Current Assets 6.1m
Non-Current Assets 37.7m
PP&E 12.6m
Intangibles 24.8m
Other Non-Current Assets 300k
Current Liabilities 18.3m
Accounts Payable 5.1m
Accrued Liabilities 12.7m
Other Current Liabilities 500k
Non-Current Liabilities 10.8m
Other Non-Current Liabilities 10.8m
Efficiency

Earnings Waterfall
Ambrx Biopharma Inc

Revenue
5.7m USD
Operating Expenses
-94m USD
Operating Income
-88.3m USD
Other Expenses
5.7m USD
Net Income
-82.6m USD

Free Cash Flow Analysis
Ambrx Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

AMAM Profitability Score
Profitability Due Diligence

Ambrx Biopharma Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Negative Revenue Growth Forecast
Negative Operating Income
Negative Net Income
Negative ROE
17/100
Profitability
Score

Ambrx Biopharma Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

AMAM Solvency Score
Solvency Due Diligence

Ambrx Biopharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Ambrx Biopharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMAM Price Targets Summary
Ambrx Biopharma Inc

Wall Street analysts forecast AMAM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMAM is 28.67 USD .

Lowest
Price Target
Not Available
Average
Price Target
28.67 USD
2% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AMAM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AMAM Price
Ambrx Biopharma Inc

1M 1M
-
6M 6M
+176%
1Y 1Y
+208%
3Y 3Y
+64%
5Y 5Y
+64%
10Y 10Y
+64%
Annual Price Range
28
52w Low
8.4
52w High
28.09
Price Metrics
Average Annual Return -62.11%
Standard Deviation of Annual Returns 21.06%
Max Drawdown -98%
Shares Statistics
Market Capitalization 1.8B USD
Shares Outstanding 63 289 200
Percentage of Shares Shorted 3.28%

AMAM Return Decomposition
Main factors of price return

What is price return decomposition?

AMAM News

Other Videos

Last Important Events
Ambrx Biopharma Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Ambrx Biopharma Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Ambrx Biopharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.8B USD

Dividend Yield

0%

Description

Ambrx Biopharma Inc. operates as a clinical-stage biologics company. The company is headquartered in La Jolla, California and currently employs 70 full-time employees. The company went IPO on 2021-06-18. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation. Its SAA incorporation technology allows to develop a wide array of product candidate modalities, such as antibody-drug conjugates (ADCs), bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates (ISACs). Its lead ADC candidate is ARX788, an anti-HER2 ADC, being investigated in multiple clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer and other solid tumors.

Contact

CALIFORNIA
La Jolla
10975 North Torrey Pines Road, Roadla Jolla
+18587293339.0
https://ambrx.com/

IPO

2021-06-18

Employees

70

Officers

CEO, President & Director
Mr. Daniel J. O'Connor J.D.
Chief Financial Officer
Ms. Sonja Nelson CPA
Chief Operating Officer
Mr. Andrew P. Aromando
Chief Technology Officer
Dr. Ying J. Buechler Ph.D.
Chief Scientific Officer & GM of China
Dr. Shawn Shao-Hui Zhang Ph.D.
Senior VP, General Counsel & Corporate Secretary
Mr. Jared Kelly
Show More
Vice President of Human Capital
Mr. Robert Azzara
Chief Clinical Officer
Dr. Sandra Aung Ph.D.
Chief Regulatory Officer
Ms. Renu Vaish M.Sc.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AMAM stock?

The intrinsic value of one AMAM stock under the Base Case scenario is 0.63 USD.

Is AMAM stock undervalued or overvalued?

Compared to the current market price of 28 USD, Ambrx Biopharma Inc is Overvalued by 98%.